AI in Mental Health: McGill Douglas Insights | AcademicJobs
Discover how McGill's Douglas Research Centre is advancing AI applications in mental health, from depression CDSS to biobanks, amid Canada's access crisis.
No reviews yet. Be the first to rate David!
David Benrimoh is an Assistant Professor in the Department of Psychiatry at McGill University. He holds an MDCM from McGill University, an MSc in Neuroscience from University College London where he worked with Karl Friston on computational models of auditory hallucinations, a second MSc in Psychiatry from McGill University, and is a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC). He completed his psychiatry residency at McGill University and a fellowship in Neuropsychiatry at Stanford University, where he conducted research on the mechanistic underpinnings of rapid-acting repetitive transcranial magnetic stimulation (rTMS).
Dr. Benrimoh leads the McGill Lab for Computational Psychiatry and Translation (McPsyt Lab), with research focused on computational psychiatry approaches to understanding and predicting psychosis onset, transdiagnostic imaging in psychosis, machine learning and artificial intelligence applications in mental health, digital health tools, and the development of novel treatment paradigms including neuromodulation. He is the founder and chief science officer of Aifred Health, a digital mental health company that develops AI-enabled clinical decision support tools; the company placed second in the global IBM-sponsored AI XPRIZE competition, winning $1 million USD. He has authored numerous peer-reviewed publications and received awards including the Young Investigator Award from the American Neuropsychiatric Association in 2023, the McGill Psychiatry Chairman’s Prize, the CSCI/CIHR Resident Research Award, and multiple other McGill Psychiatry prizes for research excellence. Clinically, he works in psychotic disorders with a focus on early psychosis and neuropsychiatry.
Discover how McGill's Douglas Research Centre is advancing AI applications in mental health, from depression CDSS to biobanks, amid Canada's access crisis.